Skip to main content
. 2005 Sep 19;146(6):769–780. doi: 10.1038/sj.bjp.0706396

Figure 2.

Figure 2

The tumor specificity of 17AAG, a geldanamycin analog inhibitor of Hsp90. 17AAG has a 100-times higher affinity towards the tumor-specific Hsp90 complexed by a large number of cochaperones than to the Hsp90 dimer, which is the predominant form of this chaperone in normal cells (Kamal et al., 2003; Lee et al., 2004).